Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.73 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071565 | 0.88 | SCN9A (0.73) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL962699 | 0.85 | SCN9A (1.00) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL67329 | 0.85 | SCN9A (1.00) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL29379049 | 0.85 | SCN9A (1.00) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL67328 | 0.85 | SCN9A (1.00) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL1069559 | 0.84 | MAOB (0.70) | SCN9AMAOBPARP10MAOA | |
| Ralfinamide SCHEMBL1697253 | 0.84 | SCN9A (0.98) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL1697252 | 0.84 | SCN9A (0.98) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL963780 | 0.84 | SCN9A (0.73) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL5684423 | 0.84 | SCN9A (0.70) | SCN9ASCN3AMAOBPARP15PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| EP-1658062-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARM SPA (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| EP-2029130-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | claimed |
| WO-2007144153-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-21 | — | — | WO | claimed |
| US-20070276046-A1 | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-11-29 | — | — | US | claimed |
| US-20070203182-A1 | Alpha-Aminoamide Derivatives Useful In The Treatment Of Restless Legs Syndrome And Addictive Disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-08-30 | — | — | US | claimed |
| EP-1737438-A1 | alpha-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2007-01-03 | — | — | EP | claimed |
| EP-1658062-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| WO-2005102300-A1 | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-11-03 | — | — | WO | claimed |
| EP-1588704-A1 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-26 | — | — | EP | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | PSEN1, MAPT, AADAT | SCN9A 3223/4885SCN3A 2574/4885MAOB 709/4885 |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | IL1A, AADAT, DNPEP | SCN9A 2253/4885SCN3A 1328/4885MAOB 1206/4885 |
| US-20070203182-A1 | Alpha-Aminoamide Derivatives Useful In The Treatment Of Restless Legs Syndrome And Addictive Disorders | PNMT, AADAT, BCAT2 | SCN9A 963/4885SCN3A 360/4885MAOB 73/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | SCN9A 946/4885SCN3A 372/4885MAOB 53/4885 |
| US-20070276046-A1 | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents | IL1A, AADAT, DNPEP | SCN9A 2253/4885SCN3A 1328/4885MAOB 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.